Skip to main content
Premium Trial:

Request an Annual Quote

BTIG Initiates Coverage of Fulgent Genetics

NEW YORK ­– Investment bank BTIG has initiated coverage of Fulgent Genetics with a Buy rating and a $20 price target.

In a research note on Thursday, BTIG analyst Sung Ji Nam wrote that Fulgent has shown growth over the past several years.

"We anticipate this strong growth momentum to continue over the next few years with FLGT's expanding product offerings and customer base," Nam wrote. "With the company's focus on operational efficiency, we believe FLGT has the cost structure to reach sustainable profitability relatively sooner than its peer group of molecular genetic testing service companies."

Based in Temple City, California, Fulgent offers clinical genetic testing using next-generation sequencing. The firm also has a consumer-oriented testing firm, Picture Genetics.

In morning trading on the Nasdaq, shares of Fulgent were up 4 percent at $16.70.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.